Cumberland Pharmaceuticals Inc.

NasdaqGS:CPIX Stock Report

Market Cap: US$88.8m

Cumberland Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CPIX?
Owner TypeNumber of SharesOwnership Percentage
Institutions2,809,08418.7%
General Public5,941,10839.7%
Individual Insiders6,232,91541.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 59.5% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
38%
A. Kazimi
5,695,310US$33.8m-0.1%no data
3.69%
Ikarian Capital, LLC
553,153US$3.3m-0.5%0.47%
3.14%
Renaissance Technologies LLC
470,696US$2.8m-0.31%no data
2.41%
Vanguard Capital Management, LLC
361,759US$2.1m0%no data
2.02%
Kenneth Krogulski
302,338US$1.8m1.96%no data
1.84%
Dimensional Fund Advisors LP
276,359US$1.6m1.5%no data
1.31%
Perceptive Advisors LLC
196,978US$1.2m-42.3%0.02%
1.09%
Bridgeway Capital Management, LLC
163,468US$969.4k0%0.01%
0.85%
Boothbay Fund Management, LLC
127,694US$757.2k-0.63%0.02%
0.76%
Geode Capital Management, LLC
114,293US$677.8k6.54%no data
0.54%
J. Goldman & Co., L.P.
81,040US$480.6k-14.3%0.02%
0.42%
Joseph Galante
63,656US$377.5k2.91%no data
0.39%
BNY Asset Management
58,458US$346.7k-19.4%no data
0.38%
BlackRock, Inc.
56,891US$337.4k8.21%no data
0.31%
James Jones
46,863US$277.9k3.99%no data
0.3%
Vanguard Fiduciary Trust Company
45,623US$270.5k0%no data
0.3%
Acadian Asset Management LLC
44,288US$262.6k0%no data
0.28%
GVC Gaesco Gestion SGIIC SA
42,418US$251.5k0%0.03%
0.26%
State Street Global Advisors, Inc.
39,510US$234.3k17.2%no data
0.26%
James Herman
38,255US$226.9k0%no data
0.24%
Marex Group Limited
36,423US$216.0k0%no data
0.23%
Caroline Young
35,109US$208.2k5.4%no data
0.16%
XTX Markets Limited
24,006US$142.4k0%no data
0.14%
Arrowstreet Capital, Limited Partnership
20,252US$120.1k0%no data
0.13%
John Hamm
20,073US$119.0k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/12 15:08
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cumberland Pharmaceuticals Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
David WindleyJefferies LLC
Marc GoodmanUBS Investment Bank